Pitch Creative Edge (FITX) by describing the breadth of their subsidiaries. Save Cen Biotech for last and ease into their current construction of the facility. Mention how quickly the development has gone with production and then, perhaps, share pictures of Before and After development on the land if you're able. Let them know that Health Canada has, not only, given FITX the ready to build letter, but has contacted them urging them to speed up development to reach the growing need of patients in Canada. Mention that once development of certain "pieces" of the puzzle FITX can call for license from Health Canada and they should get the license first try, (even if they don't all they need to do is correct the design that doesn't meet Health Canada's requirements and call back for another inspection. Mention Bill and his plans. Then describe how Bill's clarity and experience outlines a true leader. Perhaps let them hear Bill speak in one of his interviews. Let them know that the company has the right to import and export products once licensed. Mention who has be recently got to join the FITX team - especially John Germinario - also highlight his experience and alongside John bring up the experience of Push Point Management Group and Push Point Media Group. Outline Bill's plans to uplist (to OTC or preferably NASDAQ) and his plans to buy back shares (he would rather not have to use a reverse split). Tell them that the stock has been susceptible to some fluctuations as of late because of their status as a marijuana stock, but looking at their CEO, COB and business model they are the most likely to be successful. Their operations are fast, transparent and all filings they complete must be viewed by John Germinario. Lastly, let them know that FITX has the goal of making $250M during their first year in production - that their application is to grow 1.3Million pounds of Marijuana per year and that in the future if all of their produced product were sold they would be capable of bringing in $5 Billion from just Cen Biotech's facility in Lakeshore.
Pitch Creative Edge (FITX) by describing the breadth of
Scroll down for more posts ▼
Top 10 Most Recent News Articles
WHO and RCSI Bahrain Join Forces on Health Initiatives
Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...
Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine
Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...
Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes
Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....
Continue Reading
Webull Faces Class Action: Key Details for Investors
What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...
Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results
Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...
Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early
Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...
Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion
Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...
Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices
Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...
Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms
Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...
Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG
New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...
Continue Reading
